drugset / Trial / NCT04796012
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This trial is a multi-center, non-randomized, open-label Phase I/II study evaluating the feasibility and efficacy of vincristine, irinotecan, temozolomide, and atezolizumab in children with relapsed/refractory solid tumors.
Timeline
- Start
- 2023-04-18
- Primary completion
- 2027-01
- Completion
- 2027-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Temozolomide | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |